Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
ForestPrune: High-ratio Visual Token Compression for Video Multimodal Large Language Models via Spatial-Temporal Forest Modeling
arXiv:2603.22911v1 Announce Type: cross Abstract: Due to the great saving of computation and memory overhead, token compression has become a research hot-spot for MLLMs and achieved remarkable progress in image-language tasks. However, for the video, existing methods still fall short of high-ratio token compression. We attribute this shortcoming to the insufficient modeling of temporal and continual video content, and propose a novel and training-free token pruning method for video MLLMs, terme
-
Nature Cancer
-
Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma
Nature Cancer, Published online: 25 March 2026; doi:10.1038/s43018-026-01136-zCzernilofsky et al. identified factors that reprogram stromal cells into an inflammatory, dysfunctional state, leading to the structural disorganization of lymph nodes in B cell lymphoma at single-cell and spatial resolutions.
Reprogramming of stroma-derived chemokine networks drives the loss of tissue organization in nodal B cell lymphoma
Nature Cancer, Published online: 25 March 2026; doi:10.1038/s43018-026-01136-z
Czernilofsky et al. identified factors that reprogram stromal cells into an inflammatory, dysfunctional state, leading to the structural disorganization of lymph nodes in B cell lymphoma at single-cell and spatial resolutions.-
Oncogene - Issue - nature.com science feeds
-
TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation
Oncogene, Published online: 24 March 2026; doi:10.1038/s41388-026-03728-6TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation
TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation
Oncogene, Published online: 24 March 2026; doi:10.1038/s41388-026-03728-6
TRIM21-mediated degradation of HILPDA overcomes anti-PD-1 immunotherapy resistance in breast cancer by limiting PD-L1 palmitoylation-
Omics In Lung
-
Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer
J Inflamm Res. 2026 Mar 17;19:581764. doi: 10.2147/JIR.S581764. eCollection 2026.ABSTRACTImmune checkpoint inhibitors (ICIs) have significantly improved the clinical outcomes for patients with non-small cell lung cancer (NSCLC). However, patient heterogeneity and the limitations of current biomarkers contribute to variations in therapeutic responses. Identifying potential beneficiaries of immunotherapy and predicting efficacy remain critical challenges. In recent years, artificial intelligence (
Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer
J Inflamm Res. 2026 Mar 17;19:581764. doi: 10.2147/JIR.S581764. eCollection 2026.
ABSTRACT
Immune checkpoint inhibitors (ICIs) have significantly improved the clinical outcomes for patients with non-small cell lung cancer (NSCLC). However, patient heterogeneity and the limitations of current biomarkers contribute to variations in therapeutic responses. Identifying potential beneficiaries of immunotherapy and predicting efficacy remain critical challenges. In recent years, artificial intelligence (AI) has become increasingly applied in cancer treatment, particularly for modeling clinical data and predicting patient prognosis. By integrating multi-omics data such as radiomics, pathomics, genomics, transcriptomics, proteomics, and microbiomics, AI enables comprehensive biomarker discovery and facilitates prediction of immunotherapy responses and potential toxicities in NSCLC patients. Despite these advancements, challenges such as data standardization, limited interpretability, and technical barriers persist. This review summarizes the application of AI in predicting immunotherapy efficacy for NSCLC patients and discusses the challenges and future directions in the context of precision medicine.
PMID:41867453 | PMC:PMC13005593 | DOI:10.2147/JIR.S581764